Protagenic Therapeutics (OTCMKTS:PTIX) and PFSweb (NASDAQ:PFSW) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
Profitability
This table compares Protagenic Therapeutics and PFSweb’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Protagenic Therapeutics | N/A | -3,445.12% | -315.61% |
PFSweb | 0.25% | 12.07% | 3.14% |
Insider & Institutional Ownership
57.7% of PFSweb shares are owned by institutional investors. 51.1% of Protagenic Therapeutics shares are owned by company insiders. Comparatively, 6.5% of PFSweb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Protagenic Therapeutics and PFSweb, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Protagenic Therapeutics | 0 | 0 | 0 | 0 | N/A |
PFSweb | 0 | 1 | 3 | 0 | 2.75 |
PFSweb has a consensus price target of $10.33, indicating a potential upside of 157.05%. Given PFSweb’s higher probable upside, analysts plainly believe PFSweb is more favorable than Protagenic Therapeutics.
Risk & Volatility
Protagenic Therapeutics has a beta of -7.94, suggesting that its stock price is 894% less volatile than the S&P 500. Comparatively, PFSweb has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Earnings & Valuation
This table compares Protagenic Therapeutics and PFSweb’s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Protagenic Therapeutics | N/A | N/A | -$2.56 million | N/A | N/A |
PFSweb | $326.16 million | 0.24 | $1.23 million | N/A | N/A |
PFSweb has higher revenue and earnings than Protagenic Therapeutics.
Summary
PFSweb beats Protagenic Therapeutics on 9 of the 10 factors compared between the two stocks.
About Protagenic Therapeutics
About PFSweb
Receive News & Ratings for Protagenic Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Protagenic Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.